"After reading that it doesn’t look that successful."
I beg to differ.
Rather than 2 out of 10 people dying on placebo, only 1 out of 10 did on active treatment:
"At both the 28-day and the 60-day final time points, the biotech said “approximately 50% trend in mortality reduction (22.5% vs 10.8%) was observed."
Those are odds I'd take any day.
IPIX' COVID-19 study doesn't have mortality as a primary endpoint, of course, so unless they smash the days to recovery out of the park in order to reach significance on the primary endpoint, the study will tell us nothing bout its effect on mortality.
Which is a shame.
News 
Market Data 
Discover 
